The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Axelle Nzokirantevye Sandra Collette Maria Debiec-Rychter Steinar Aamdal Piotr Rutkowski Raf Sciot Viktor Grünwald Sandrine Marréaud Sandra J Strauss Patrick Schöffski |
| Publication date | March 20, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |